Pharmacological characterisation of cannabinoid CB1 receptors in the rat and mouse

European Journal of Pharmacology

Volumn 391, Issue 1-2, 2000, Pages 151-161

  Lay, Lucy ^a   Angus, James A ^a   Wright, Christine E ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

9 Tetrahydrocannabinol; Anandamide; Cannabinoid CB1 receptor; CP 55,940; SR 141716A; SR 144528; Sympathetic neurotransmission

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANANDAMIDE; ATROPINE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; DRONABINOL; METHOXAMINE; NORADRENALIN; RIMONABANT;

ADRENERGIC TRANSMISSION; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HEART RIGHT ATRIUM; MESENTERIC ARTERY; MOUSE; NONHUMAN; PRESYNAPTIC NERVE; PRIORITY JOURNAL; RAT; RESISTANCE BLOOD VESSEL; SMOOTH MUSCLE CONTRACTION; VAS DEFERENS;

ANIMALS; ARACHIDONIC ACIDS; BORNANES; CANNABINOIDS; CYCLOHEXANOLS; HEART ATRIA; MALE; MESENTERIC ARTERY, INFERIOR; MICE; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB2; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; SYMPATHETIC NERVOUS SYSTEM; SYNAPTIC TRANSMISSION; TETRAHYDROCANNABINOL; VAS DEFERENS; VASCULAR RESISTANCE;

EID: 0034629113     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00062-5     Document Type: Article

References (47)

1. Angus J.A., Broughton A., Mulvany M.J. Role of α-adrenoceptors in constrictor responses of rat, guinea pig and rabbit small arteries to neural activation. J. Physiol. 403:1988;495-510.
2. Angus J.A., Harvey K. Refractory period field stimulation of right atria: a method for studying pre-synaptic receptors in cardiac autonomic transmission. J. Pharmacol. Methods. 6:1981;51-64.
3. Chakrabarti A., Onaivi E.S., Chaudhuri G. Cloning and sequencing of a cDNA encoding the mouse brain-type cannabinoid receptor protein. DNA Sequence. 5:1995;385-388.
4. Colquhoun D. Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br. J. Pharmacol. 125:1998;924-947.
5. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty acid amides. Nature. 384:1996;83-87.
6. Deutsch D.G., Chin S.A. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol. 46:1993;791-796.
7. Deutsch D.G., Goligorsky M.S., Schmid P.C., Krebsbach R.J., Schmid H.H.O., Das S.K., Dey S.K., Arreaza G., Thorup C., Stefano G., Moore L.C. Production and physiological actions of anandamide in the vasculature of the rat kidney. J. Clin. Invest. 100:1997;1538-1546.
8. Devane W.A., Dysarz III F.A., Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:1988;605-613.
9. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Graeme G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
10. Galiègue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., Bouaboula M., Shire D., Le Fur G., Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232:1995;54-61.
11. 1 receptors on peripheral sympathetic nerves. Br. J. Pharmacol. 118:1996;2023-2028.
12. 1 receptor. Eur. J. Pharmacol. 334:1997;R1-R2.
13. 1 agonists and antagonist display tissue and species differences in rat and mouse. IUPHAR. Vol. 358:1998;R222 Naunyn-Schmiedeberg, München.
14. Lew M.J., Angus J.A. Analysis of competitive agonist-antagonist interactions by non-linear regression. Trends Pharmacol. Sci. 16:1995;328-337.
15. Ludbrook J. Repeated measurements and multiple comparisons in cardiovascular research. Cardiovasc. Res. 28:1994;303-311.
16. Mackie K., Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl. Acad. Sci. U.S.A. 89:1992;3825-3829.
17. 2 receptors. Br. J. Pharmacol. 124:1998;619-622.
18. Molderings G.J., Göthert M. Pre-synaptic imidazoline receptors mediate inhibition of noradrenaline release from sympathetic nerves in rat blood vessels. Fundam. Clin. Pharmacol. 12:1998;388-397.
19. Molderings G.J., Likungu J., Göthert M. Pre-synaptic cannabinoid and imidazoline receptors in the human heart and their potential relationship. Naunyn-Schmiedeberg's Arch. Pharmacol. 360:1999;157-164.
20. Mulvany M.J., Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ. Res. 41:1977;19-26.
21. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
22. 1 cannabinoid receptor activity. Mol. Pharmacol. 54:1998;1064-1072.
23. Pertwee R., Griffin G., Fernando S., Li X., Hill A., Makriyannis A. AM630, a competitive cannabinoid receptor antagonist. Life Sci. 56:1995;1949-1955.
24. 1 receptors in mouse urinary bladder. Br. J. Pharmacol. 118:1996;2053-2058.
25. Pertwee R.G., Fernando S.R., Griffin G., Abadji V., Makriyannis A. Effect of phenylmethylsulphonyl fluoride on the potency of anandamide as an inhibitor of electrically evoked contractions in two isolated tissue preparations. Eur. J. Pharmacol. 272:1995b;73-78.
26. 1 receptors in guinea pig small intestine. Br. J. Pharmacol. 118:1996a;2199-2205.
27. Pertwee R.G., Griffin G. A preliminary investigation of the mechanisms underlying cannabinoid tolerance in the mouse vas deferens. Eur. J. Pharmacol. 272:1995;67-72.
28. Pertwee R.G., Griffin G., Lainton J.A.H., Huffman J.W. Pharmacological characterization of three novel cannabinoid receptor agonists in the mouse isolated vas deferens. Eur. J. Pharmacol. 284:1995;241-247.
29. 1 receptors in mouse vas deferens. Eur. J. Pharmacol. 296:1996;169-172.
30. Pertwee R.G., Stevenson L.A., Elrick D.B., Mechoulam R., Corbett A.D. Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea pig small intestine. Br. J. Pharmacol. 105:1992;980-984.
31. Pertwee R.G., Stevenson L.A., Griffin G. Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940,WIN 55,212-2 and anandamide. Br. J. Pharmacol. 110:1993;1483-1490.
32. Randall M.D., Alexander S.P.H., Bennett R., Boyd E.A., Fry J.R., Gardiner S.M., Kemp P.A., McCulloch A.I., Kendall D.A. An endogenous cannabinoid as an endothelium-derived vasorelaxant. Biochem. Biophys. Res. Commun. 229:1996;114-120.
33. Randall M.D., Kendall D.A. Involvement of a cannabinoid in endothelium-derived hyperpolarizing factor-mediated coronary vasorelaxation. Eur. J. Pharmacol. 335:1997;205-209.
34. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G., Caput D., Ferrara P., Soubrie P., Breliere J.C., Le Fur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
35. 2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284:1998;644-650.
36. 1 cannabinoid receptor isoforms. J. Pharmacol. Exp. Ther. 278:1996;871-878.
37. 2 peripheral cannabinoid receptor. Biochem. Biophys. Acta. 1307:1996;132-136.
38. Shire D., Carillon C., Kaghad M., Calandra B., Rinaldi-Carmona M., Le Fur G., Caput D., Ferrara P. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J. Biol. Chem. 270:1995;3726-3731.
39. 35S]thio]-triphosphate binding. Proc. Natl. Acad. Sci. U.S.A. 92:1995;7242-7246.
40. Snedecor G.W., Cochran W.G. Statistical Methods. 1989;Iowa State University Press, Ames.
41. 2 values and associated analysis. J. Pharmacol. Exp. Ther. 207:1978;705-718.
42. Ward S.J., Mastriani D., Casiano F., Arnold R. Pravadoline: profile in isolated tissue preparations. J. Pharmacol. Exp. Ther. 255:1990;1230-1239.
43. White R., Hiley C.R. A comparison of EDHF-mediated and anandamide-induced relaxations in the rat isolated mesenteric artery. Br. J. Pharmacol. 122:1997;1573-1584.
44. White R., Hiley C.R. The actions of the cannabinoid receptor antagonist, SR 141716A, in the rat isolated mesenteric artery. Br. J. Pharmacol. 125:1998;689-696.
45. Wright C.E., Angus J.A. Effects of N-, P- and Q-type neuronal calcium channel antagonists on mammalian peripheral neurotransmission. Br. J. Pharmacol. 119:1996;49-56.
46. Wright C.E., Angus J.A., Korner P.I. Vascular amplifier properties in renovascular hypertension in conscious rabbits. Hindquarter responses to constrictor and dilator stimuli. Hypertension. 9:1987;122-131.
47. Zygmunt P.M., Hogestatt E.D., Waldeck K., Edwards G., Kirkup A.J., Weston A.H. Studies on the effects of anandamide in rat hepatic artery. Br. J. Pharmacol. 122:1997;1679-1686.